RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

No need to apologize--I wish I was more sure of the answers. One thing I am not sure about is: What proportion of people who apply to be in the study will turn out to have clearcut sleep apnea, which is consistent in terms of apnea episode frequency over time? DavidAl might know....

But this means we do not know how many people have to be screened (and fees paid for) in order to get n=20. We also don't know if they are going to require that at least a couple of them have a diagnosis of central/mixed apnea--which is about 15% of the apnea population, since CX717 might work differently in that population than in obstructive sleep apnea. This is why I am reluctant to presume/predict a shorter timeline.

Secondly--why on earth would you assume that a CRO would accept deferred payment? If anything, in dealing with a company running out of money, they don't want to end up one of the unpaid creditors, so they probably want most of the money as contracted elements of the study are completed.

I don't know what the cost of the study is, but I'd bet it's closer to a million dollars than $600K. It's hard to go wrong guessing on the high side in the pharma world.

NeuroInvestment